Company profile
UK company 12151270, incorporated on 12 August 2019.
GenomeKey - Unlocking DNA
Using whole genome sequencing and novel machine learning, GenomeKey diagnoses bacterial presence, species and antimicrobial resistance in only hours, not days, at low cost.
Company number 12151270
Financial period: 1 Sep 2024 to 31 Aug 2025
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
1 Jul 2025 to 28 Feb 2026
GenomeKey is developing a revolutionary environmental monitoring system for pharmaceutical manufacturing that combines proprietary microfluidic concentration technology with next-generation DNA sequencing to enable rapid detection and identification of microbial contaminants. Current pharmaceutical quality control relies on traditional culture-based testi...
1 Jul 2023 to 30 Jun 2025
GenomeKey is developing a next-generation diagnostic device for bacterial blood infections. Our diagnostic will result in earlier and more accurate detection and diagnosis of bacterial sepsis, and faster antimicrobial susceptibility results, leading to better treatment, patient outcomes and considerable treatment cost savings. In addition, our device will...
1 May 2022 to 31 Oct 2023
GenomeKey is developing a next-generation point-of-care diagnostic device for bacterial blood infections in cases of sepsis. Our diagnostic will result in earlier and more accurate detection and diagnosis of bacterial sepsis, and faster antimicrobial susceptibility results, leading to better treatment, patient outcomes and considerable treatment cost savi...
1 Jan 2021 to 31 Mar 2021
GenomeKey determines how to treat Sepsis in hours, rather than days. This is important because Sepsis now kills more people than cancer, and can kill within hours. For a patient admitted to a hospital today, they would wait 3 days before the doctor knows which antibiotic will fight the infection. GenomeKey reduces this time using cutting edge machine lear...
